Previous Close | 35.47 |
Open | 35.60 |
Bid | 0.00 x 900 |
Ask | 0.00 x 900 |
Day's Range | 35.13 - 38.35 |
52 Week Range | 22.01 - 47.48 |
Volume | 149,374 |
Avg. Volume | 117,666 |
Market Cap | 531.48M |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.30 |
Earnings Date | Mar 04, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52.00 |
BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, March 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10012940. A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika investor relations website. The call will be archived and accessible on the same website shortly after its conclusion. About Anika Therapeutics, Inc. Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com. For Investor Inquiries:Anika Therapeutics, Inc.Mark Namaroff, 781-457-9287Executive Director, Investor Relations and Corporate Communicationsinvestorrelations@anika.com
Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.
Today we will run through one way of estimating the intrinsic value of Anika Therapeutics, Inc. ( NASDAQ:ANIK ) by...